Systematic review: Clostridium difficile and inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 4, 2011, Pages 428-441

  Goodhand, J R ^a   Alazawi, W ^a   Rampton, D S ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIFAXIMIN; STEROID; TINIDAZOLE; VANCOMYCIN;

ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLON RESECTION; CROHN DISEASE; DIARRHEA; ENTERITIS; FECES CULTURE; GASTROINTESTINAL ENDOSCOPY; HUMAN; ILEITIS; INCIDENCE; LENGTH OF STAY; MORTALITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; RELAPSE; REMISSION; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78751545522     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04548.x     Document Type: Article

References (83)

1. Finney J,. Gastro-enterostomy for circatrizing ulcer of the pylorus. Bull Johns Hopkins Hosp 1893; 4: 53.
2. Hall IC, O' Toole E,. Intestinal flora in new born infants: with a description of a new pathogenic anaerobe, bacillus difficilis. Am J Dis Child 1935; 49: 390.
3. Tedesco FJ, Barton RW, Alpers DH,. Clindamycin-associated colitis. A prospective study. Ann Intern Med 1974; 81: 429-33.
4. Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB,. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978; 75: 778-82.
5. Healthcare Protection Agency. Clostridium Difficile Infection: How to Deal With the Problem. London: Health Protection Agency, 2008.
6. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466-72.
7. McFarland LV,. Renewed interest in a difficult disease: Clostridium difficile infections-epidemiology and current treatment strategies. Curr Opin Gastroenterol 2009; 25: 24-35.
8. Ananthakrishnan AN, Issa M, Binion DG,. Clostridium difficile and inflammatory bowel disease. Gastroenterol Clin North Am 2009; 38: 711-28.
9. Issa M, Ananthakrishnan AN, Binion DG,. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1432-42.
10. Musa S, Thomson S, Cowan M, Rahman T,. Clostridium difficile infection and inflammatory bowel disease. Scand J Gastroenterol 2010; 45: 261-72.
11. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
12. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK,. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28: 140-5. (Pubitemid 46374153)
13. Bland JM, Kerry SM,. Statistics notes. Weighted comparison of means. BMJ (Clinical research ed) 1998; 316: 129.
14. Bolton RP, Sherriff RJ, Read AE,. Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease? Lancet 1980; 1: 383-4.
15. Brown WJ, Hudson MJ, Patrick S, et al. Search for enteric microbial pathogens in patients with ulcerative colitis. Digestion 1992; 53: 121-8.
16. Burke DA, Axon AT,. Clostridium difficile, sulphasalazine, and ulcerative colitis. Postgrad Med J 1987; 63: 955-7.
17. Dorman SA, Liggoria E, Winn WC Jr, Beeken WL,. Isolation of Clostridium difficile from patients with inactive Crohn's disease. Gastroenterology 1982; 82: 1348-51.
18. Greenfield C, Aguilar Ramirez JR, Pounder RE, et al. Clostridium difficile and inflammatory bowel disease. Gut 1983; 24: 713-7.
19. Gryboski JD,. Clostridium difficile in inflammatory bowel disease relapse. J Pediatr Gastroenterol Nutr 1991; 13: 39-41.
20. Gurian L, Klein K, Ward TT,. Role of Clostridium difficile and Campylobacter jejuni in relapses of inflammatory bowel disease. West J Med 1983; 138: 359-60.
21. Gursoy S, Guven K, Arikan T, et al. Clostridium difficile infection frequency in patients with nosocomial infections or using antibiotics. Hepatogastroenterology 2007; 54: 1720-4.
22. Jonard PP, Fiasse R, Delmeee M, Vanheuverzwijn R, Dive C,. Clostridium difficile and its toxin in a series of cases of Crohn's disease and ulcerative colitis. Acta Gastroenterol Belg 1983; 46: 220-9.
23. Keighley MR, Youngs D, Johnson M, Allan RN, Burdon DW,. Clostridium difficile toxin in acute diarrhoea complicating inflammatory bowel disease. Gut 1982; 23: 410-4.
24. Lishman AH, Al-Jumaili IJ, Record CO,. Spectrum of antibiotic-associated diarrhoea. Gut 1981; 22: 34-7.
25. Markowitz JE, Brown KA, Mamula P, Drott HR, Piccoli DA, Baldassano RN,. Failure of single-toxin assays to detect clostridium difficile infection in pediatric inflammatory bowel disease. Am J Gastroenterol 2001; 96: 2688-90.
26. Meyer AM, Ramzan NN, Loftus EV Jr, Heigh RI, Leighton JA,. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004; 38: 772-5.
27. Meyers S, Mayer L, Bottone E, Desmond E, Janowitz HD,. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology 1981; 80: 697-700.
28. Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS,. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004; 16: 775-8.
29. Navarro-Llavat M, Domenech E, Bernal I, et al. Prospective, observational, cross-sectional study of intestinal infections among acutely active inflammatory bowel disease patients. Digestion 2009; 80: 25-9.
30. Rolny P, Jarnerot G, Mollby R,. Occurrence of Clostridium difficile toxin in inflammatory bowel disease. Scand J Gastroenterol 1983; 18: 61-4.
31. Trnka YM, LaMont JT,. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology 1981; 80: 693-6.
32. Weber P, Koch M, Heizmann WR, Scheurlen M, Jenss H, Hartmann F,. Microbic superinfection in relapse of inflammatory bowel disease. J Clin Gastroenterol 1992; 14: 302-8.
33. Willumsen L, Tvede M,. Clostridium difficile in the feces in acute diarrhea, irritable colon and ulcerative colitis. Ugeskr Laeger 1983; 145: 902-4.
34. Balamurugan R, Balaji V, Ramakrishna BS,. Estimation of faecal carriage of Clostridium difficile in patients with ulcerative colitis using real time polymerase chain reaction. Indian J Med Res 2008; 127: 472-7.
35. Hyams JS, McLaughlin JC,. Lack of relationship between Clostridium difficile toxin and inflammatory bowel disease in children. J Clin Gastroenterol 1985; 7: 387-90.
36. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-51.
37. Kochhar R, Ayyagari A, Goenka MK, Dhali GK, Aggarwal R, Mehta SK,. Role of infectious agents in exacerbations of ulcerative colitis in India. A study of Clostridium difficile. J Clin Gastroenterol 1993; 16: 26-30.
38. Pascarella F, Martinelli M, Miele E, Del Pezzo M, Roscetto E, Staiano A,. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009; 154: 854-8.
39. Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD,. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339-44.
40. Vaishnavi C, Kochhar R, Bhasin D, Thennarasu K, Singh K,. Simultaneous assays for Clostridium difficile and faecal lactoferrin in ulcerative colitis. Trop Gastroenterol 2003; 24: 13-6.
41. Wright JM, Adams SP, Gribble MJ, Bowie WR,. Clostridium difficile in Crohn's disease. Can J Surg 1984; 27: 435-7.
42. Ananthakrishnan AN, McGinley EL, Binion DG,. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57: 205-10.
43. Nguyen GC, Kaplan GG, Harris ML, Brant SR,. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 1443-50.
44. Ricciardi R, Ogilvie JW Jr, Roberts PL, Marcello PW, Concannon TW, Baxter NN,. Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases. Dis Colon Rectum 2009; 52: 40-5.
45. Wultanska D, Banaszkiewicz A, Radzikowski A, et al. Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease. Eur J Clin Microbiol Infect Dis 2010; 29: 1265-70.
46. Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG,. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2010 [Epub ahead of print].
47. Ben-Horin S, Margalit M, Bossuyt P, et al. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and clostridium difficile infection. J Crohn's Colitis 2010; 4: 194-8.
48. Ben-Horin S, Margalit M, Bossuyt P, et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin Gastroenterol Hepatol 2009; 7: 981-7.
49. Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S,. Increasing incidence of clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohn's Colitis 2009; 3: 4-7.
50. Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 2009; 104: 1162-9.
51. Jodorkovsky D, Young Y, Abreu MT,. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010; 55: 415-20.
52. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B,. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009; 30: 253-64.
53. Shen BO, Jiang ZD, Fazio VW, et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2008; 6: 782-8.
54. Dial S, Delaney JA, Schneider V, Suissa S,. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006; 175: 745-8.
55. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S,. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008; 179: 767-72.
56. Fontaine O, Ducluzeau R, Raibaud P, et al. Comparison between the number and nature of fecal clostridia and other risk factors implicated in the intestinal pathology of newborn infants. Ann Inst Pasteur Microbiol 1986; 137B: 61-75.
57. Hartley MG, Hudson MJ, Swarbrick ET, Grace RH, Gent AE, Hellier MD,. Sulphasalazine treatment and the colorectal mucosa-associated flora in ulcerative colitis. Aliment Pharmacol Ther 1996; 10: 157-63.
58. Kelsen JR, Kim J, Latta D, et al. Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2010 [Epub ahead of print].
59. Morimoto Y, Nomura K, Tsutsumi Y, et al. Clostridium difficile-associated diarrhea with hematochezia is associated with ulcer formation. Scand J Gastroenterol 2008; 43: 967-70.
60. Nash SV, Bourgeault R, Sands M,. Colonic disease associated with a positive assay for Clostridium difficile toxin: a retrospective study. J Clin Gastroenterol 1997; 25: 476-9.
61. Nomura K, Fujimoto Y, Yamashita M, et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol 2009; 44: 74-8.
62. Riley TV, Wetherall F, Bowman J, Mogyorosy J, Golledge CL,. Diarrheal disease due to Clostridium difficile in general practice. Pathology 1991; 23: 346-9.
63. Sonnenberg A,. Similar geographic variations of mortality and hospitalization associated with IBD and Clostridium difficile colitis. Inflamm Bowel Dis 2010; 16: 487-93.
64. Tedesco FJ, Hardin RD, Harper RN, Edwards BH,. Infectious colitis endoscopically simulating inflammatory bowel disease: a prospective evaluation. Gastrointest Endosc 1983; 29: 195-7.
65. Tvede M, Willumsen L,. Clostridium difficile in patients with irritable bowel syndrome and ulcerative colitis. Lancet 1982; 1: 1124.
66. Wistrom J, Norrby SR, Myhre EB, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001; 47: 43-50.
67. Banaszkiewicz A, Wultanska D, Pituch H, Radzikowski A,. Prevalence of Clostridium difficile infection in Polish pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 16: 554.
68. Navaneethan U, Shen B,. Secondary pouchitis: those with identifiable etiopathogenetic or triggering factors. Am J Gastroenterol 2010; 105: 51-64.
69. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN,. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007; 142: 624-31.
70. Bartlett JG,. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346: 334-9.
71. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-50.
72. Goodhand J, Dawson R, Hefferon M, et al. Inflammatory bowel disease in young people: the case for transitional clinics. Inflamm Bowel Dis 2010; 16: 947-52.
73. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135: 1114-22.
74. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008; 135: 1106-13.
75. Scheurer DB, Hicks LS, Cook EF, Schnipper JL,. Accuracy of ICD-9 coding for Clostridium difficile infections: a retrospective cohort. Epidemiol Infect 2007; 135: 1010-3.
76. Kaplan GG,. Administrative database studies in IBD: a cautionary tale. Am J Gastroenterol 2010; 105: 1808-10.
77. McFarland LV,. Update on the changing epidemiology of Clostridium difficile-associated disease. Nature clinical practice 2008; 5: 40-8.
78. Riley TV, Cooper M, Bell B, Golledge CL,. Community-acquired Clostridium difficile-associated diarrhea. Clin Infect Dis 1995; 20 (Suppl. 2): S263-5.
79. Kutty PK, Woods CW, Sena AC, et al. Risk Factors for and Estimated Incidence of Community-Associated Clostridium Difficile Infection. USA: Emerg Infect Dis North Carolina, 2010.
80. Moshkowitz M, Ben-Baruch E, Kline Z, Shimoni Z, Niven M, Konikoff F,. Risk factors for severity and relapse of pseudomembranous colitis in an elderly population. Colorectal Dis 2007; 9: 173-7.
81. Lundeen SJ, Otterson MF, Binion DG, Carman ET, Peppard WJ,. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. J Gastrointest Surg 2007; 11: 138-42.
82. Tsironi E, Irving PM, Feakins RM, Rampton DS,. "Diversion" colitis caused by Clostridium difficile infection: report of a case. Dis Colon Rectum 2006; 49: 1074-7.
83. Tedesco FJ,. Antibiotic-associated colitis-an abating enigma. J Clin Gastroenterol 1981; 3: 221-4.